According to a recent LinkedIn post from Medmain Inc, the company has developed an AI model designed to automatically detect Ki-67-positive cells and calculate the labeling index in immunohistochemical digital slides. The post notes that the work, related to its PidPort digital pathology support solution, has been published in the MDPI journal Diagnostics and was supported by a Fukuoka Prefecture grant.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Medmain is targeting increased automation and standardization in pathology workflows by applying cell-level classification across whole-slide images. For investors, this type of clinically oriented AI validation and peer-reviewed publication may support the credibility and adoption prospects of PidPort, potentially strengthening Medmain’s positioning within the rapidly evolving digital pathology and AI-enabled diagnostics market.
If the technology scales effectively into commercial products and integrations with hospital and laboratory systems, it could create recurring software revenue opportunities and deepen customer lock-in. However, broader financial impact will depend on regulatory pathways, reimbursement environments, competitive offerings in AI pathology, and Medmain’s ability to translate research outcomes into deployable, revenue-generating solutions across key geographies.